Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Public ClinicalTrials.gov record NCT06596694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Study identification
- NCT ID
- NCT06596694
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- Patritumab deruxtecan Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2024
- Primary completion
- Dec 6, 2028
- Completion
- Dec 6, 2028
- Last update posted
- Jun 22, 2026
2024 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology Oncology Santa Monica ( Site 1205) | Santa Monica | California | 90404 | Recruiting |
| University of Colorado Cancer Center ( Site 1200) | Aurora | Colorado | 80045 | Recruiting |
| Sibley Memorial Hospital ( Site 1208) | Washington D.C. | District of Columbia | 20016 | Recruiting |
| University of Florida ( Site 1202) | Gainesville | Florida | 32610 | Recruiting |
| Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213) | Miami Beach | Florida | 33140 | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203) | Marietta | Georgia | 30060 | Completed |
| University of Chicago Medical Center ( Site 1204) | Chicago | Illinois | 60637 | Recruiting |
| Renown Regional Medical Center ( Site 1221) | Reno | Nevada | 89502 | Recruiting |
| NYU Langone Hospital - Long Island ( Site 1230) | Mineola | New York | 11501 | Completed |
| Perlmutter NYU Cancer Center ( Site 1212) | New York | New York | 10016 | Completed |
| Scott & White Medical Center-Temple ( Site 1224) | Temple | Texas | 76508 | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207) | Roanoke | Virginia | 24014 | Recruiting |
| University of Wisconsin ( Site 1210) | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06596694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2026 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06596694 live on ClinicalTrials.gov.